Santen Pharmaceutical Co., Ltd. (SNPHF)
SNPHF Stock Price Chart
Explore Santen Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze SNPHF price movements and trends.
SNPHF Company Profile
Discover essential business fundamentals and corporate details for Santen Pharmaceutical Co., Ltd. (SNPHF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
9 Jun 2010
Employees
3.74K
Website
https://www.santen.comCEO
Takeshi Ito
Description
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
SNPHF Financial Timeline
Browse a chronological timeline of Santen Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 6 Nov 2025
Revenue estimate is $471.47M.
Earnings released on 7 Aug 2025
EPS came in at $0.12 falling short of the estimated $0.17 by -27.55%, while revenue for the quarter reached $476.97M , beating expectations by +1.00%.
Earnings released on 13 May 2025
EPS came in at $0.18 surpassing the estimated $0.12 by +53.95%, while revenue for the quarter reached $531.04M , beating expectations by +9.21%.
Dividend declared on 13 May 2025
A dividend of $0.13 per share was announced, adjusted to $0.13.
Dividend declared on 13 May 2025
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend will be paid on 1 Dec 2025.
Earnings released on 6 Feb 2025
EPS came in at $0.17 surpassing the estimated $0.00 by +13.98K%, while revenue for the quarter reached $485.71M , missing expectations by -8.45%.
Earnings released on 7 Nov 2024
EPS came in at $0.15 falling short of the estimated $0.18 by -17.25%, while revenue for the quarter reached $498.35M , missing expectations by -4.01%.
Earnings released on 6 Aug 2024
EPS came in at $0.20 surpassing the estimated $0.16 by +23.32%, while revenue for the quarter reached $465.52M , missing expectations by -0.40%.
Earnings released on 9 May 2024
EPS came in at $0.00 falling short of the estimated $0.10 by -97.94%, while revenue for the quarter reached $521.64M , missing expectations by -0.24%.
Dividend declared on 9 May 2024
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 25 Jun 2025.
Dividend declared on 9 May 2024
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 29 Nov 2024.
Earnings released on 8 Feb 2024
EPS came in at $0.14 surpassing the estimated $0.10 by +29.39%, while revenue for the quarter reached $550.61M , beating expectations by +5.42%.
Earnings released on 7 Nov 2023
EPS came in at $0.16 falling short of the estimated $0.18 by -13.60%, while revenue for the quarter reached $491.28M , beating expectations by +11.14%.
Earnings released on 3 Aug 2023
EPS came in at $0.20 surpassing the estimated $0.14 by +35.88%, while revenue for the quarter reached $500.90M , beating expectations by +6.12%.
Earnings released on 11 May 2023
EPS came in at $0.02 surpassing the estimated $0.02 by +24.91%, while revenue for the quarter reached $598.11M , beating expectations by +3.39%.
Dividend declared on 11 May 2023
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 26 Jun 2024.
Dividend declared on 11 May 2023
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 30 Nov 2023.
Earnings released on 7 Feb 2023
EPS came in at $0.11 surpassing the estimated $0.11 by +6.58%, while revenue for the quarter reached $546.37M , beating expectations by +2.73%.
Earnings released on 8 Nov 2022
EPS came in at -$0.51 falling short of the estimated $0.07 by -867.67%, while revenue for the quarter reached $438.35M , beating expectations by +0.44%.
Earnings released on 4 Aug 2022
EPS came in at $0.15 falling short of the estimated $0.15 by -3.69%, while revenue for the quarter reached $482.14M , beating expectations by +7.24%.
Earnings released on 10 May 2022
EPS came in at $0.15 falling short of the estimated $0.16 by -5.52%, while revenue for the quarter reached $576.19M , beating expectations by +2.10%.
Dividend declared on 10 May 2022
A dividend of $0.12 per share was announced, adjusted to $0.12. The dividend was paid on 28 Jun 2023.
Dividend declared on 10 May 2022
A dividend of $0.11 per share was announced, adjusted to $0.11. The dividend was paid on 30 Nov 2022.
Earnings released on 10 Feb 2022
EPS came in at $0.11 falling short of the estimated $0.13 by -14.99%, while revenue for the quarter reached $582.88M , beating expectations by +4.36%.
Earnings released on 8 Nov 2021
EPS came in at $0.15 falling short of the estimated $0.17 by -8.87%, while revenue for the quarter reached $572.53M , beating expectations by +6.02%.
Earnings released on 6 Aug 2021
EPS came in at $0.17 surpassing the estimated $0.16 by +7.07%, while revenue for the quarter reached $584.72M .
Earnings released on 11 May 2021
EPS came in at -$0.33 , while revenue for the quarter reached $613.55M .
Dividend declared on 11 May 2021
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 27 Jun 2022.
Dividend declared on 11 May 2021
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 30 Nov 2021.
Earnings released on 4 Feb 2021
EPS came in at $0.17 surpassing the estimated $0.11 by +52.37%, while revenue for the quarter reached $608.53M , missing expectations by -98.77%.
Earnings released on 6 Nov 2020
EPS came in at $0.18 surpassing the estimated $0.14 by +27.29%, while revenue for the quarter reached $581.11M , missing expectations by -98.70%.
Dividend declared on 8 May 2020
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 28 Jun 2021.
Dividend declared on 8 May 2020
A dividend of $0.13 per share was announced, adjusted to $0.13. The dividend was paid on 30 Nov 2020.
SNPHF Stock Performance
Access detailed SNPHF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.